Evidence map›Paper›PMID 41097665›Full record

ArticleCancers2025

Deferred Versus Upfront Cytoreductive Nephrectomy in MetaStatic Renal Cell Carcinoma: Comparative Survival Analysis in the Immunotherapy Era.

Tao Xu, Paerhati Tuerxun, Ning Liu, Chencheng Ji, Kunlun Zhao, Yiguan Qian, Abudukelimu Abudushataer, Yang Li, Xiaotian Jiang, Zhongli Xiong and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tao XuGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Paerhati TuerxunDepartment of Urology, Yining People's Hospital, Yining 835099, China.
Ning LiuDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Chencheng JiDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Kunlun ZhaoDepartment of Urology, Yining People's Hospital, Yining 835099, China.
Yiguan QianDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Abudukelimu AbudushataerDepartment of Urology, Yining People's Hospital, Yining 835099, China.
Yang LiDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0002-4277-9214
Xiaotian JiangDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Zhongli XiongDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Min WangDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Ruipeng JiaDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Yu-Zheng GeDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0003-1615-9473

Funding

Jiangsu Province's high-level talent training program 2024-3-2367Nanjing Medical Science and Technology Development Foundation for Distinguished Young Scholars JQX18003Research Project of Xinjiang Uygur Autonomous Region Health Commission 2025001QNKYXM654021877Science and Technology Planning Project of Ili Kazakh Autonomous Prefecture YJC2025A14Young Elite Scientists Sponsorship Program by Jiangsu Association for Science and Technology JSTJ-2024-387Youth Medical Talent Program of Jiangsu Province QNRC2016073
6 · The paper itself

Abstract

backgroundThe optimal timing of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains a subject of debate, particularly in the immunotherapy era. This study compares survival outcomes between deferred CN (dCN) and upfront CN (uCN) in mRCC patients receiving modern immunotherapy regimens in the real-world setting.

methodsWe retrospectively analyzed the SEER database for mRCC patients diagnosed between 2016 and 2021 who underwent dCN or uCN. The primary endpoint was overall survival (OS), while the secondary endpoints were disease-specific survival (DSS) and other-cause specific survival (OCSS). Statistical analyses included propensity score matching (PSM), Kaplan-Meier survival curves, Cox proportional hazards modeling, as well as sensitivity, subgroup, and landmark analyses.

resultsA total of 1892 mRCC patients were included, with 346 patients (18.3%) undergoing dCN and 1546 patients (81.7%) receiving uCN. Patients in the uCN group were characterized with lower T stage (

conclusionsdCN may be associated with improved survival outcomes compared to uCN in selected mRCC patients receiving immunotherapy, and careful patient selection for dCN or uCN is essential.

Indexed as

cytoreductive nephrectomyimmunotherapymetastatic renal cell carcinomapopulation-based analysissurgery timing

Identifiers

PMID41097665
PMCPMC12523447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.